Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc

Bullboard Posts

Comment by rjc7on Jan 04, 2016 11:47am

117 Views

Post# 24427738

RE:RE:RE:RE:RE:RE:News release comments

Still doesn't matter. "In fiscal 2015, the Company advised the partner of the recent completion of its
Lumisort™ prototype technology, and offered the partner the opportunity as a distributor
of this technology, which the partner declined" Meaning, they still declined the deal sometime in 2015.

Bullboard Posts

Day trading vs. swing trading strategies for small-cap stocks